Tezepelumab
Generic name
Tezepelumab
Brand name
ATC Code
R03DX11
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Based on population pharmacokinetic analysis, there was no clinically meaningful age-related difference in the pharmacokinetics of tezepelumab between adults and adolescents aged 12 to 17 years. The following pharmacokinetic parameters are known: (SmPC Tezspire)
| Tmax | 3 - 10 days (following a single subcutaneous administration) |
| Bioavailability (F) | 77% |
| Cl | 0,17 L/d* |
| Vd, central | 3,9 L* |
| Vd, peripheral | 2,2 L* |
| T1/2 | 26 days |
* based on population pharmacokinetic analysis for a 70 kg individual
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Adjuvant treatment in severe asthma |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The safety profile in adolescents does not differ from that in adults.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Xanthines | ||
|---|---|---|
| R03DA04 | ||
| Leukotriene receptor antagonists | ||
|---|---|---|
| R03DC03 | ||
| Other systemic drugs for obstructive airway diseases | ||
|---|---|---|
| R03DX09 | ||
| R03DX05 | ||
Reference
- AstraZeneca AB, SmPC Tezspire (EU/1/22/1677/001) Rev4. 19-4-2023, www.ema.europa.eu
Changes
Therapeutic Drug Monitoring
Overdose
